Under-expression of VHL and over-expression of HDAC-1, HIF-1α, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis

International Journal of Dermatology

Volumn 46, Issue 3, 2007, Pages 239-246

  Tovar Castillo, Laura E ^a,b   Cancino Díaz, Juan C ^a,b   García Vázquez, Francisco ^a,b   Cancino Gómez, Francisco G ^a,b   León Dorantes, Gladys ^a,b   Blancas González, Fernando ^a,b   Jiménez Zamudio, Luis ^a,b   García Latorre, Ethel ^a,b   Cancino Díaz, Mario E ^a,b  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INHIBITOR; APOPTOSIS INHIBITOR PROTEIN 2; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; FAS ANTIGEN; FAS LIGAND; HISTONE DEACETYLASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PR 39; PROTEIN BAX; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; PSORIASIS SEVERITY INDEX; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY;

ADULT; AGED; ANTIMICROBIAL CATIONIC PEPTIDES; BIOPSY; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; PSORIASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33847793536     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.02962.x     Document Type: Article

References (25)

1. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-1675.
2. Detmar M, Brown LF, Claffey KP, et al. Over expression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180: 1141-1146.
3. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev 2003; 3: 721-732.
4. Li J, Post M, Volk R, et al. PR39, a peptide regulator of angiogenesis. Nat Med 2000; 6: 49-55.
5. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylase induces angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-443.
6. Iliopoulos O, Levy AP, Jiang C. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci 1996; 93: 10 595-10 599.
7. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003; 111: 1665-1672.
8. Wu J, Parungo C, Wu G, et al. PR39 inhibits apoptosis in hypoxic endothelial cells. Role of inhibitor apoptosis protein-2. Circulation 2004; 109: 1660-1667.
9. Sørensen O, Cowland J, Theilgaarda-Mönch K, et al. Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol 2003; 170: 5583-5589.
10. Krane JF, Gottlieb AB, Carter M, et al. The insulin growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. J Exp Med 1992; 175: 1081-1090.
11. Frohm M, Agerberth B, Ahangari G, et al. The expression of the gene coding for antibacterial peptide LL37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 1997; 272: 15 258-15 263.
12. Li D, Li J, Duan Y, et al. Expression of LL-37, human beta defensin-2, and CCR6 mRNA in patients with psoriasis vulgaris. J Huazhong Univ Soc Technol Med Sci 2004; 14: 404-406.
13. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-1160.
14. Bjorntorp E, Wickelgren R, Bjarnason R, et al. No evidence for involvement of the growth hormone/insulin-like growth factor-1 axis in psoriasis. J Invest Dermatol 1997; 109: 661-665.
15. Warren R, Yuan H, Matli MR, et al. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 1996; 271: 29 483-29 488.
16. Kwon YW, Kwon KS, Moon HE, et al. Insulin-like growth factor-II regulates the expression of vascular endothelial growth factor by the human keratinocyte cell line HaCaT. J Invest Dermatol 2004; 123: 152-158.
17. Kamura T, Sato S, Iwai K, et al. Activation of HIF alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci 2000; 97: 10 430-10 435.
18. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2: 423-427.
19. Gnarra JR, Zhou S, Merril MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of VHL tumor suppressor gene. Proc Natl Acad Sci 1996; 93: 10 589-10 594.
20. Siemeister G, Weindel K, Mohrs K, et al. Endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996; 56: 2299-2201.
21. Datta K, Nambudripad R, Pal S, et al. Inhibition of insulin-like growth factor I mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem 2000; 275: 20 700-20 706.
22. Wrone-Smith T, Johnson T, Nelson B, et al. Discordant expression of Bcl-X and Bcl-2 by keratinocytes in vitro and psoriasic keratinocytes in vivo. Am J Pathol 1995; 146: 1079-1088.
23. Kocak M, Bozdogan O, Erkek E, et al. Examination of Bcl-2, Bcl-X and Bax protein expression in psoriasis. Int J Dermatol 2003; 42: 789-793.
24. Takahashi H, Manabe A, Ishida-Yamamoto A, et al. Aberrant expression of apoptosis-related molecules in psoriatic epidermis. J Dermatol Sci 2002; 28: 187-197.
25. Yamamoto T, Nishioka K. Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy. Skin Pharmacol Appl Skin Physiol 2003; 16: 50-58.